Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has received a consensus recommendation of “Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $9.00.
Several equities analysts have recently weighed in on PYXS shares. Stifel Nicolaus started coverage on Pyxis Oncology in a report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday, September 19th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Friday, August 16th.
View Our Latest Stock Report on PYXS
Hedge Funds Weigh In On Pyxis Oncology
Pyxis Oncology Trading Down 2.7 %
PYXS stock opened at $3.62 on Friday. The stock has a market cap of $215.10 million, a PE ratio of -2.66 and a beta of 1.28. The stock has a 50-day moving average price of $3.61 and a two-hundred day moving average price of $3.91. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. On average, analysts forecast that Pyxis Oncology will post -1.07 earnings per share for the current fiscal year.
Pyxis Oncology Company Profile
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Recommended Stories
- Five stocks we like better than Pyxis Oncology
- Insider Selling Explained: Can it Inform Your Investing Choices?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Stock Market Upgrades: What Are They?
- MarketBeat Week in Review – 9/23 – 9/27
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.